恒瑞医药(600276.SH)：SHR-1905注射液获得药物临床试验批准

Core Viewpoint - Heng Rui Medicine's subsidiary received approval from the National Medical Products Administration for clinical trials of SHR-1905 injection, a monoclonal antibody targeting TSLP, aimed at improving inflammation and controlling disease progression [1] Group 1: Product Development - SHR-1905 injection is designed to block the release of inflammatory cytokines and inhibit downstream inflammatory signaling [1] - The global market has a similar product, Tezepelumab, which is projected to generate approximately $1.22 billion in sales in 2024 [1] - The cumulative R&D investment for SHR-1905 injection has reached approximately 209.62 million yuan [1]